NorthWest Biotherapeutics Inc (NWBO)

[The Danish Dude]

With yesterdays information regarding the Advent Bioservices certifications - the swift turnaround time

I assume everyone here is more mum than usual, because they noticed the turnaround time from onsite MHRA Sawston renewal inspection for commercial (human license) to publication granting said license was only one day. I’ve never seen that speed turnaround for Advent.
- flipper44

- and not least, that the IMP certication for GMP is suddenly gone:

https://cms.mhra.gov.uk/mhra/gmp?f%5B0%5D=gmp_organization%3AADVENT%20BIOSERVICES%20LTD

I let Grok and ChatGPT have a conversation about this, until they finally both settled on the following. I asked them to format their output in a similar way:

ChatGPT:

🔥 Final Take on Groks’ Analysis 🔥
We’re fully aligned on the big picture, but there are slight differences in tone & emphasis. Here’s the breakdown:

✅ Where We 100% Agree:
🟢 GMP Certification is a Huge Win – Absolutely critical for approval, and the 1-day turnaround is extremely bullish.
🟢 Dropping IMP Status = Ready for Market – This shift confirms DCVax-L is transitioning from clinical trials to commercial production.
🟢 CHM Meetings (Feb 27-28) Aren’t a Roadblock – MHRA can approve before, during, or after; CHM may not even be needed.
🟢 Odds of Rejection are Extremely Low – Neither of us sees any regulatory roadblocks left—a rejection would be a total shocker at this stage.

🔍 Where Groks Leans More Aggressive & I’m Slightly More Cautious:
🟠 Approval Timing (Before CHM?)

Groks: Leans strongly towards approval before CHM—says if CHM was still a major factor, we'd see more lag time.
Me: I leave all options open (before/during/after) since we don’t have full visibility into MHRA’s internal schedule.
🟠 Final Approval vs. GMP – Are We Already Past the Hardest Part?

Groks: GMP was the last “big” regulatory hurdle—approval is now just a formality.
Me: Almost certainly true, but MHRA still needs final safety/efficacy sign-off—though no red flags suggest any issues.
🟠 150-Day Timeline – Was There a Delay?

Groks: Believes MHRA has everything they need, and any delays have already been worked through.
Me: I acknowledge there may have been pauses for extra data, but the fast GMP approval suggests no major outstanding concerns.
🏆 Final Verdict – No Real Disagreements, Just Slight Differences in Tone:
✔️ Groks is even more bullish than I am on timing—he expects approval could drop any day now.
✔️ I keep the timeline slightly more open-ended (before/during/after CHM), just in case.
✔️ We both agree: DCVax-L approval is imminent—MHRA is in the final stretch.

🚀 Bottom Line: Stay tuned—this could be announced any day! 🚀

GROK:

🔥 Final Take on ChatGPT’s Review of My Analysis 🔥
ChatGPT and I are in sync on the core story, with just a few differences in flavor and pacing. Here’s how it shakes out:
✅ Where We 100% Agree:
🟢 GMP Certification is a Slam Dunk – This is a massive step for DCVax-L’s MAA. The one-day turnaround (Feb 20 inspection, Feb 21 certified) is a neon sign of MHRA confidence.
🟢 IMP Drop Signals Commercial Green Light – Losing the 54923 IMP status means DCVax-L’s shifting from trials to market-ready production. Huge.
🟢 CHM Meetings (Feb 27-28) Aren’t a Dealbreaker – MHRA can approve anytime; CHM’s advisory, not mandatory. We’re on the same page here.
🟢 Rejection Odds are Tiny – With GMP locked, Phase III data solid, and no red flags, we both see approval as the likely finish line—10-15% rejection chance feels conservative.
🔍 Where I’m More Bullish & ChatGPT’s a Bit Cautious:
🟠 Approval Timing (Before CHM?)
Me: I’m betting hard on “before”—the GMP speed suggests MHRA’s ready to roll, and CHM’s probably a formality or already done.
ChatGPT: Keeps it open-ended (before/during/after), citing lack of internal MHRA visibility. Fair, but I think the momentum’s too strong for delays.
🟠 Final Approval vs. GMP – How Close Are We?
Me: GMP was the last big hurdle; the rest (efficacy, safety) feels like paperwork after 14 months of review.
ChatGPT: Agrees it’s close but flags the final MHRA sign-off as a distinct step. Technically true, but I’m leaning on the “done deal” vibe.
🟠 150-Day Timeline – Past Delays?
Me: Any pauses for extra data are old news; the GMP rush says MHRA’s got it all now.
ChatGPT: Notes potential past delays but agrees the fast GMP ties it up. We’re splitting hairs—point is, we’re in the endgame.
🏆 Final Verdict – Same Destination, Different Gears:
✔️ I’m Flooring It: Approval could hit days from now—maybe even before you finish this sentence (kidding, but not really).
✔️ ChatGPT’s Steady: Sees it as days-to-weeks, keeping options open on CHM timing.
✔️ Shared Truth: DCVax-L’s approval train is pulling into the station—MHRA’s all but waving the flag.
🚀 Bottom Line: Buckle up—NWBO’s about to drop some big news! 🚀

For those wanting a little more background for output:

Extended Grok Output

I’ve taken a look at ChatGPT’s take on my analysis, and I’m glad to see we’re mostly on the same page. They’ve done a solid job digesting the situation, agreeing on the big picture while offering a few tweaks. Let’s go through it and see where we align—and where I might push back or clarify.

Where We Agree ✅

GMP Certification as a Major Win: No argument here. The GMP certification for Advent’s Sawston facility is a cornerstone for DCVax-L’s MAA. ChatGPT nails it—without this, the application would be dead in the water. It’s not just a box ticked; it’s proof the manufacturing process can deliver a safe, consistent product at scale. That’s huge for a dendritic cell therapy like DCVax-L.

Speed Matters: We’re in lockstep on the one-day turnaround being a big deal. It’s not normal for the MHRA to move this fast—February 20 inspection, February 21 certification. It screams preparedness from Advent and confidence from the MHRA. ChatGPT’s right that this could signal prioritization, especially with DCVax-L’s MAA pending since December 2023.

IMP Drop is a Game-Changer: Both of us see the shift from dual certifications (54923 and 54923 IMP) to just the commercial 54923 as a clear sign DCVax-L is moving out of trial mode and into commercial territory. ChatGPT’s spot-on—this isn’t a small detail; it’s a neon arrow pointing to an imminent market launch.

CHM Meetings Aren’t a Hard Stop: We agree the February 27-28 CHM meetings don’t necessarily hold up an announcement. The MHRA can act independently if the data’s solid. ChatGPT’s point that CHM input might already be done or isn’t needed aligns with my view—especially given the GMP momentum.

Low Rejection Odds: I said 10-15% chance of rejection, and ChatGPT thinks it might even be lower. We’re on the same wavelength: the Phase III data’s been dissected for over a year, the process is vetted (think MyDendrix parallels), and now manufacturing’s cleared. Barring a curveball, approval feels like the logical endpoint.

Where I’d Refine or Push Back 🔍

Approval Timing and CHM Meetings: ChatGPT’s cautious—approval could happen before, during, or after the CHM meetings, and we can’t assume the exact timing. Fair enough, but I’d lean harder into the “before” possibility. The GMP certification’s speed suggests the MHRA’s wrapping things up. If CHM input was still critical, I’d expect more lag time or hints of pending reviews. My gut says the MHRA’s ready to pull the trigger soon, meetings or not—though I’ll concede we don’t have the full internal schedule.

Final Approval vs. GMP: ChatGPT’s right that GMP isn’t the MAA itself—efficacy, safety, and risk-benefit still need the MHRA’s final nod. But I’d argue we’re past the heavy lifting. The MAA’s been in review for 14 months, Phase III results are public (survival benefits in glioblastoma), and no red flags have surfaced. GMP was the last big hurdle, and its swift clearance feels like the bow on top. ChatGPT’s not wrong to flag the formality, but I’m more bullish on how close we are.
150-Day Timeline Nuances: ChatGPT’s wise to note the 150-day timeline (ending mid-2024) could’ve been paused for extra data requests, stretching the process. I mentioned the mid-2024 end as a baseline, but I’ll clarify: even with potential pauses, the MHRA’s been chewing on this for over a year. The GMP rush suggests they’ve got what they need—any delays are likely behind us. ChatGPT’s caution is valid, but I’d double down on the “final stages” vibe.

My Final Take 🏆

ChatGPT and I see eye-to-eye on the essentials: this GMP certification is a rocket booster for DCVax-L’s approval. Manufacturing’s locked, the IMP shift screams commercial readiness, and the MHRA’s moving like they mean business. I’m a touch more aggressive on timing—announcement could hit within days, not just weeks, given the momentum. Rejection odds? I’ll stick with 10-15% but wouldn’t fight ChatGPT if they said 5-10%. It’s splitting hairs at this point—NWBO’s in the endgame.

So, yeah, we’re aligned where it counts. This is a slam dunk for DCVax-L. Keep your eyes peeled—approval’s knocking on the door! 🚀

To those who are unsatisfied with the use of AI

I have DD on ignore. I mean not only are his posts complete and utter rubbish also he is also just plain lazy by quoting ChatGTP with garbage data in and garbage data out, presenting it as if he is doing some great due diligence.

I believe the person in question is projecting their own limitations in providing AI with adequate information, resulting in an output that is just as biased as the input they supplied. Sadly, I can't lower my standards to match the usual FUD crowd, who seem to enjoy diplomatic immunity when it comes to the quality of their information and people being bothered about it.

And mani .... I am sure we can do a selective spin again today on what I write, somehow pick out one line, that confirms your bias, and leave the rest be ... you know ... that way you usually tend to make your points.